HEXIM1 and glioblastoma: We have previously reported that BETi-specific responses can be measured in orthotopic GBM xenografts measuring BETi-responsive gene signatures of interest, including the pharmacologic marker for target engagement of BETi, HEXIM1 that is rapidly upregulated [6].